Fierce Biotech reports (via Bloomberg) that Actelion is rumored to be the next takeover target in biotech - and the named suitor of the moment is rumored to be Amgen. The rumor apparently a result of Amgen's failure to definitely deny that they are looking at Actelion as a takeover target - and Actelion stating that they always talk to potential suitors (without naming names) as a matter of course.
It takes no more than that to get a good rumor off the ground. Regardless of validity, investors are buying up Actelion stock. Amgen is rumored to be in process of making offer. Roche is rumored to be waiting in wings to also potentially make an offer for the company it helped get started 13 years ago with a portfolio of unwanted molecules that it spun out to Actelion.
Posted by Bruce Lehr November 17th 2010.